Lignospan

Lidocaine hydrochloride, the active ingredient in Lignospan, is a local anesthetic presented as a solution for dental use. It provides rapid onset of local anesthesia for dental procedures, acute dental pain and pulpitis in patients requiring intra‑oral treatment.

GNH USA supplies Lignospan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lignospan is a local anesthetic solution used in dental practice to manage pain and facilitate procedures.

- Dental procedures requiring local anesthesia: provides numbness of the targeted area to allow painless treatment. - Management of acute dental pain: rapidly reduces pain associated with dental trauma or infection. - Pulpitis: alleviates inflammation‑related discomfort during endodontic therapy.

Adverse reactions may occur following administration of Lignospan.

Common Side Effects: - Transient burning or stinging at the injection site. - Tingling or mild numbness that persists briefly after the procedure. - Localized swelling or bruising. - Headache or light‑headedness. - Dizziness. - Mild increase in heart rate.

Serious or Rare Side Effects: - Allergic reaction including rash, itching, or anaphylaxis. - Significant hypertension or tachycardia. - Cardiac arrhythmias or myocardial ischemia. - Seizures due to excessive lidocaine levels. - Prolonged or profound numbness affecting speech or swallowing. - Severe hypotension.

Prior to using Lignospan, clinicians should consider several safety measures.

- Allergy assessment: verify no known hypersensitivity to lidocaine, epinephrine or related compounds. - Cardiovascular caution: avoid or use with extreme care in patients with uncontrolled hypertension, arrhythmias or severe coronary disease. - Beta‑blocker interaction: monitor for altered heart‑rate responses when patients are on non‑selective beta‑blockers. - Drug‑interaction review: assess concurrent use of MAO inhibitors or other sympathomimetics. - Aseptic technique: ensure sterile handling to prevent infection at the injection site. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lignospan may interact with other medications; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - MAO inhibitors: combined use with epinephrine can precipitate hypertensive crisis. - Non‑selective beta‑blockers: may mask epinephrine‑induced tachycardia and increase blood pressure. - Tricyclic antidepressants: can potentiate lidocaine toxicity, leading to CNS effects. - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiac conduction disturbances. - Monoamine oxidase inhibitors: heightened risk of severe hypertension.

Moderate Interactions (Monitor Closely): - Other local anesthetics: cumulative lidocaine exposure may raise toxicity risk. - CYP450 inhibitors (e.g., cimetidine, fluoroquinolones): may slow lidocaine metabolism. - Sympathomimetic drugs (e.g., phenylephrine): additive vasoconstrictive effects. - Diuretics: may alter plasma electrolyte balance affecting lidocaine action. - Antihypertensive agents: monitor blood pressure for additive effects.